Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Eli Lilly and Company
Age
18–85
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Normal Participants:
Healthy male and female participants as determined by physical examination
Participants with normal renal function assessed by estimated glomerular filtration rate (eGFR) ≥ 90 milliliter per minute (mL/min).
Body mass index (BMI) ≥ 19.0 and ≤ 40.0 kilograms per meter squared (kg/m²)
Male participants who agree to use contraception and female participants of child bearing potential must agree to use contraceptive methods and women not of child bearing potential can participate.
Participants with Renal Impairment:
Have acceptable blood pressure (BP) and pulse rate, as determined by the investigator
Participants with type 2 diabetes must have a glycated hemoglobin (HbA1c) ≥ 5.0% and ≤ 11.5%
Are males or females with severe renal impairment as determined by a stable eGFR \<30 mL/min, not requiring hemodialysis OR
Are males or females with end-stage renal disease (have received hemodialysis for at least 3 months)
You may not be if
Have known allergies to LY3437943 or related compounds
Have a current, functioning organ transplant. Nonfunctional renal allografts may be allowed
Have any abnormality in the 12-lead electrocardiogram (ECG)
Are women with a positive pregnancy test or women who are lactating
Clareo Health | A Study of LY3437943 in Healthy Participants and Participants With Impaired Renal Function
